Effect of intramuscular 15-methyl prostaglandin F2 alpha after second-trimester delivery. 1997

S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
Department of Obstetrics and Gynecology, Arnold Palmer Hospital for Children and Women, Division of Orlando Regional Healthcare System, Florida, USA.

OBJECTIVE To determine whether 15-methyl prostaglandin (PG) F2 alpha shortens the third stage of labor in second-trimester pregnancy loss. METHODS This was a randomized, double-blind, placebocontrolled study of women between 13 and 28 weeks' gestation admitted for spontaneous or induced pregnancy termination. Subjects were randomized on admission to receive either PG (250 micrograms) or placebo (normal saline), 1 mL intramuscularly every 20 minutes, for a maximum of three doses if the placenta had not delivered spontaneously within 10 minutes of the fetus. A dilute oxytocin infusion was given to women in both groups. The patients were managed expectantly with hourly vaginal examinations until intervention was required or up to 6 hours, when curettage was scheduled. RESULTS Thirty-eight women received PG and 29 received placebo. There was no difference between the groups with regard to method of pregnancy termination or gestational age. There was a statistically significant decrease in the time from first injection to placental delivery (40.0 versus 92.5 minutes; P = .02) between the PG and control groups, respectively. CONCLUSIONS The therapeutic use of PG in the third stage of labor in second-trimester pregnancy loss reduces the time to complete spontaneous placental delivery.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D010120 Oxytocics Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157) Oxytocic,Oxytocic Agent,Oxytocic Drug,Uterine Stimulant,Uterine Stimulants,Oxytocic Agents,Oxytocic Drugs,Oxytocic Effect,Oxytocic Effects,Agent, Oxytocic,Agents, Oxytocic,Drug, Oxytocic,Drugs, Oxytocic,Effect, Oxytocic,Effects, Oxytocic,Stimulant, Uterine,Stimulants, Uterine
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011262 Pregnancy Trimester, Second The middle third of a human PREGNANCY, from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation. Midtrimester,Pregnancy, Second Trimester,Trimester, Second,Midtrimesters,Pregnancies, Second Trimester,Pregnancy Trimesters, Second,Second Pregnancy Trimester,Second Pregnancy Trimesters,Second Trimester,Second Trimester Pregnancies,Second Trimester Pregnancy,Second Trimesters,Trimesters, Second
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015237 Dinoprost A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. PGF2,PGF2alpha,Prostaglandin F2,Prostaglandin F2alpha,9alpha,11beta-PGF2,Enzaprost F,Estrofan,PGF2 alpha,Prostaglandin F2 alpha,9alpha,11beta PGF2,F2 alpha, Prostaglandin,F2alpha, Prostaglandin,alpha, PGF2

Related Publications

S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
April 1983, Contraceptive delivery systems,
S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
May 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
May 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
November 1976, Contraception,
S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
January 1983, The Indian journal of medical research,
S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
April 1979, Journal of obstetrics and gynaecology of India,
S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
March 1975, Contraception,
S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
September 1979, Southern medical journal,
S J Carlan, and J P Gushwa, and W F O'Brien, and T Vu
December 1984, Asia-Oceania journal of obstetrics and gynaecology,
Copied contents to your clipboard!